secwatch.observer — SEC 8-K summary
======================================

Issuer:     Unity Biotechnology, Inc. (—)
CIK:        0001463361
Form:       8-K
Filed at:   2025-05-05T23:59:59+00:00
Accession:  0000950170-25-063167
Event type: other_material
Sentiment:  negative
Materiality: 1.00
Item codes: 2.05, 8.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Unity Biotech lays off all employees, explores strategic alternatives after Phase 2b miss
--------------------------------------------------------------------------------

- Company reducing entire workforce; expects $3.7M in severance and related cash costs; completion by May 15, 2025.
- CEO Anirvan Ghosh, CFO Lynne Sullivan, and Chief Legal Officer Alexander Nguyen will terminate employment May 15, transition to advisory consulting roles.
- Phase 2b ASPIRE study of UBX1325 in DME showed non-inferiority to aflibercept at week 36 but missed primary endpoint at average of weeks 20 and 24.
- Strategic alternatives include sale, license, monetization, merger, or wind-down of the company; no assurance of any transaction.
- Cash and equivalents $16.9M as of March 31, 2025; company reducing operational cash burn.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1463361/000095017025063167/0000950170-25-063167-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1463361/000095017025063167/ubx-20250502.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-063167

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer